These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Deremer DL; Ustun C; Natarajan K Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785 [TBL] [Abstract][Full Text] [Related]
7. Pathological findings suggesting vascular endothelial damage in multiple organs in chronic myelogenous leukemia patients on long-term tyrosine kinase inhibitor therapy. Seki Y; Nagano O; Koda R; Morita S; Hasegawa G Int J Hematol; 2020 Oct; 112(4):584-591. PubMed ID: 32557125 [TBL] [Abstract][Full Text] [Related]
8. Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond. Jabbour E; Cortes J; Giles F; O'Brien S; Kantarijan H IDrugs; 2007 Jul; 10(7):468-79. PubMed ID: 17642017 [TBL] [Abstract][Full Text] [Related]
9. [Nilotinib as a second-line treatment for chronic myeloid leukemia]. Yamauchi T; Ueda T Gan To Kagaku Ryoho; 2011 Jun; 38(6):911-5. PubMed ID: 21677481 [TBL] [Abstract][Full Text] [Related]
10. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Steinberg M Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072 [TBL] [Abstract][Full Text] [Related]
11. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. le Coutre PD; Giles FJ; Hochhaus A; Apperley JF; Ossenkoppele GJ; Blakesley R; Shou Y; Gallagher NJ; Baccarani M; Cortes J; Kantarjian HM Leukemia; 2012 Jun; 26(6):1189-94. PubMed ID: 22076466 [TBL] [Abstract][Full Text] [Related]
12. Nilotinib-Associated Atherosclerosis Presenting as Multifocal Intracranial Stenosis and Acute Stroke. Kakadia B; Thakkar R; Sanborn E; Suero-Abreu GA; Jovin TG; Then R J Stroke Cerebrovasc Dis; 2021 Aug; 30(8):105883. PubMed ID: 34090174 [TBL] [Abstract][Full Text] [Related]
13. Changes from imatinib mesylate to second generation tyrosine kinase inhibitors improve renal impairment with imatinib mesylate in chronic myelogenous leukemia. Hino A; Yoshida H; Tada Y; Koike M; Minami R; Masaie H; Ishikawa J Int J Hematol; 2016 Nov; 104(5):605-611. PubMed ID: 27460678 [TBL] [Abstract][Full Text] [Related]
14. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Kim TD; Rea D; Schwarz M; Grille P; Nicolini FE; Rosti G; Levato L; Giles FJ; Dombret H; Mirault T; Labussière H; Lindhorst R; Haverkamp W; Buschmann I; Dörken B; le Coutre PD Leukemia; 2013 Jun; 27(6):1316-21. PubMed ID: 23459449 [TBL] [Abstract][Full Text] [Related]
15. Hematological and molecular response evaluation of CML patients on imatinib. Gupta A; Prasad K J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739 [TBL] [Abstract][Full Text] [Related]
16. [A case of recurrent cerebral infarction during treatment with oral tyrosine kinase inhibitors for chronic myelogenous leukemia]. Nakaya A; Ebitani M; Monzen T; Nagno T; Saito F; Yaoita Y Rinsho Shinkeigaku; 2019 Jul; 59(7):418-424. PubMed ID: 31243247 [TBL] [Abstract][Full Text] [Related]
17. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389 [TBL] [Abstract][Full Text] [Related]
18. Bullous sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABL- positive lesional cells. Kaune KM; Baumgart M; Gesk S; Mitteldorf C; Baesecke J; Glass B; Haase D; Siebert R; Ghadimi BM; Neumann C; Emmert S Arch Dermatol; 2008 Mar; 144(3):361-4. PubMed ID: 18347292 [TBL] [Abstract][Full Text] [Related]
19. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Irvine E; Williams C Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study. Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]